29
Sat, Apr
19 New Articles
  • Alder BioPharmaceuticals Presents Positive Phase 2b Study Data for Eptinezumab at 69th Annual American Academy of Neurology Meeting

    Apr 28, 2017 | 17:24 pm

    - Eptinezumab emerging clinical profile suggests migraine preventative benefit achieved as soon as 24 to 48 hours after a single infusion -BOTHELL, Wash., April28, 2017(GLOBE NEWSWIRE) --  Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced the presentation of positive data from its Phase 2b clinical trial evaluating eptinezumab (formerly ALD403) for the prevention of migraine.Key[…]

    Read more...
  • Sartorius Stedim Biotech Introduces New BIOSTAT STR® Bioreactor Range

    Apr 28, 2017 | 09:45 am

    Sartorius Stedim Biotech (http://www.sartorius-stedim.com) (SSB), a leading international supplier for the biopharmaceutical industry, announced the launch of its next generation BIOSTAT STR® (http://www.sartorius.com/biostat-str), a fully scalable, single-use bioreactor family based on a conventional stirred-tank design. This new bioreactor range featuring upgraded hardware and software, as well as a

    Read more...
  • Intercept to Report First Quarter 2017 Financial Results on May 4 and Present at Upcoming Conference

    Apr 27, 2017 | 21:00 pm

    NEW YORK, April27, 2017(GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it will report its first quarter 2017 financial results prior to the NASDAQ market open on Thursday, May 4, 2017. Intercept management will conduct a conference call and audio[…]

    Read more...
  • Progenics Pharmaceuticals Sets First Quarter 2017 Financial Results Call for May 4

    Apr 27, 2017 | 20:30 pm

    NEW YORK, April27, 2017(GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc., (Nasdaq:PGNX), an oncology company developing innovative medicines and other products for targeting and treating cancer, announced today that it will host a conference call and webcast to review the first quarter ended March 31, 2017 financial results on Thursday, May 4, 2017, at 8:30 a.m. ET.To participate, please dial (877) 250-8889[…]

    Read more...
  • Alder BioPharmaceuticals® Announces First Quarter 2017 Financial and Operating Results

    Apr 27, 2017 | 20:05 pm

    Top-line data from pivotal PROMISE 1 study of eptinezumab for migraine prevention on track to be announced 2Q 2017Conference call set for 5 p.m. EDT todayBOTHELL, Wash., April27, 2017(GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced financial results for the first quarter ended March 31, 2017, and provided a corporate update.“During[…]

    Read more...
  • Myriad Genetics and Clovis Oncology Sign Agreement for Use of FDA-Approved BRACAnalysis CDx® Test to Identify Patients with Germline BRCA Mutations for Rubraca® (rucaparib) Treatment

    Apr 27, 2017 | 11:05 am

    SALT LAKE CITY and BOULDER, Colo., April27, 2017(GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) and Clovis Oncology, Inc. (NASDAQ:CLVS) today announced a companion diagnostic collaboration to support a post-marketing regulatory commitment related to Clovis’ PARP inhibitor, Rubraca.  Financial terms of the deal were not disclosed.Under the agreement, Myriad will submit a supplementary premarket approval (sPMA) application under its existing PMA[…]

    Read more...
  • MacroGenics Announces Registered Direct Offering of Common Stock

    Apr 27, 2017 | 11:00 am

    Rockville, MD, April27, 2017(GLOBE NEWSWIRE) ---- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced that it has entered into a definitive agreement with an institutional healthcare investor to purchase 1,100,000 shares of its Common Stock at a[…]

    Read more...
  • ProQR Announces Clearance of IND Application to Start Clinical Trial for QR-110 in Leber’s Congenital Amaurosis Type 10 Patients

    Apr 27, 2017 | 11:00 am

    Key updatesWith the clearance of the investigational new drug (IND) application by the U.S. Food and Drug Administration (FDA), ProQR can now start clinical development of QR-110 in Leber’s congenital amaurosis Type 10 (LCA 10) patientsLCA 10 is one of the most prevalent forms of gene-related blindness in children worldwide and currently there are no therapies commercially availableThe Phase 1/2[…]

    Read more...
  • ChromaDex Announces Strategic Investment Led by Mr. Li Ka-shing

    Apr 27, 2017 | 10:30 am

    IRVINE, Calif., April27, 2017(GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness and nutritional ingredients that creates science-based solutions for dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that it has entered into a securities purchase agreement for the sale of up to $25 million of its common stock in a[…]

    Read more...
  • Onconova Therapeutics Announces Closing of Public Offering of Common Stock

    Apr 26, 2017 | 21:25 pm

    NEWTOWN, Pa., April26, 2017(GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS), today announced the closing of its previously announced public offering of 2,476,190 shares of its common stock at a price to the public of[…]

    Read more...
  • AXIM Biotech to Present at ExcipientFest 2017 in Providence, Rhode Island

    Apr 26, 2017 | 13:00 pm

    NEW YORK, April26, 2017(GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that Lekhram Changoer, Chief Technology Officer of AXIM Biotech, will deliver keynote presentation at the upcoming ExcipientFest 2017, to be held from April 25-26, 2017 at The Rhode Island Convention Center (RICC) in Providence, RI.Mr. Changoer will present[…]

    Read more...
  • MacroGenics to Present at Two Upcoming Investor Conferences in May

    Apr 26, 2017 | 11:00 am

    Rockville, MD, April26, 2017(GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced that the Company's management will present at two upcoming conferences, including:Deutsche Bank 42nd Annual Health Care Conference in Boston on Wednesday, May[…]

    Read more...
  • Amarin to Report First Quarter 2017 Resultsand Host Conference Call on May 3, 2017

    Apr 25, 2017 | 20:30 pm

    BEDMINSTER, N.J., and DUBLIN, Ireland, April25, 2017(GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to discuss the company's first quarter 2017 financial results and provide an operational update on Wednesday, May[…]

    Read more...
  • MacroGenics Announces Date of First Quarter 2017 Financial Results Conference Call

    Apr 25, 2017 | 20:30 pm

    ROCKVILLE, MD, April25, 2017(GLOBE NEWSWIRE) -- -- MacroGenics, Inc. (Nasdaq: MGNX) today announced that on Wednesday, May 3, 2017, the Company will release its financial results for the quarter ended March 31, 2017. The Company's management team will host a conference call discussing the Company's financial results and recent corporate developments on Wednesday, May 3, 2017 at 4:30 pm (ET).[…]

    Read more...
  • BeyondSpring Enrolls First U.S. Patient in Phase 2/3 Clinical Trial of Plinabulin for Neutropenia Prevention

    Apr 25, 2017 | 12:30 pm

    NEW YORK, April25, 2017(GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the Company has enrolled the first patient at the Hematology / Oncology Northshore, Illinois, in its Phase 2/3 study of BeyondSpring’s lead asset, Plinabulin, for the prevention of neutropenia, in combination with docetaxel.“We have[…]

    Read more...
  • Galectin Therapeutics Receives Notice of Japanese Decision to Grant a Composition of Matter Patent for GR-MD-02

    Apr 25, 2017 | 12:00 pm

    NORCROSS, Ga., April25, 2017(GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis, skin diseases, and cancer, today announced that the Company has received a Decision to Grant from the Japanese Patent Office for its patent application for "Composition of Novel Carbohydrate Drug for Treatment of Human Diseases." When issued, the patent will extend[…]

    Read more...
  • RedHill Biopharma Announces Enrollment of Last Patient in the BEKINDA® Phase II Study for IBS-D

    Apr 24, 2017 | 11:15 am

    Top-line results are expected in the third quarter of 2017The randomized, double-blind, placebo-controlled Phase II study is evaluating the safety and efficacy of BEKINDA® (RHB-102) 12 mg in 127 U.S. patients with diarrhea-predominant irritable bowel syndrome (IBS-D)IBS is one of the most common gastrointestinal disorders; it is estimated that at least 30 million Americans suffer from IBS, of which over[…]

    Read more...
  • Polyganics Announces Enrollment of the First Patient in its PROTECT NEURO Study

    Apr 20, 2017 | 08:00 am

    Polyganics (http://www.polyganics.com/), a privately held medical technology company focused on the commercialization of proprietary products and technologies for peripheral nerve reconstruction and regeneration, announced today that it has enrolled the first patient in its international PROTECT NEURO study to treat and prevent symptomatic neuroma. The first patient was treated at Stanford Medicine by Catherine Curtin, MD, associate professor of surgery.The[…]

    Read more...
  • Reinhard Kandera Appointed Chief Financial Officer of Hookipa Biotech

    Apr 19, 2017 | 07:00 am

    Hookipa Biotech AG (http://hookipabiotech.com/), a company pioneering a new class of immunotherapies for oncology and infectious diseases, today announces that Reinhard Kandera has joined the Company as Chief Financial Officer (CFO). Effective June 1st, 2017, he will also become a member of Hookipa’s management board.Reinhard Kandera has more than 20 years of professional experience in the finance and healthcare industries[…]

    Read more...
  • RedHill Biopharma Receives Notice of Allowance for Two Additional U.S. Patents Covering BEKINDA®

    Apr 18, 2017 | 12:45 pm

    RedHill received Notices of Allowance from the United States Patent and Trademark Office (USPTO) for two new patents covering BEKINDA® (RHB-102), expected to be valid until at least 2034, once grantedBEKINDA® is a proprietary, bimodal extended-release, once-daily oral pill formulation of ondansetron, targeting several gastrointestinal indicationsTop-line results from a Phase III study with BEKINDA® 24 mg for acute gastroenteritis and[…]

    Read more...
  • Agendia Appoints Patrick J. Balthrop Sr., Former CEO of Luminex, as Chairman

    Apr 12, 2017 | 20:15 pm

    Agendia, Inc. (http://www.agendia.com/), a world leader in personalized medicine and molecular cancer diagnostics, today announces the appointment of Patrick J. Balthrop Sr., former CEO of Luminex, as Non-Executive Chairman.“Patrick’s knowledge and experience in driving rapid growth in technology-led companies is exceptional, and will bolster Agendia’s position in the sector,” said Mark R. Straley, CEO of Agendia. “Agendia is committed to[…]

    Read more...
  • LDC and SOTIO Enter License and Collaboration Agreement for First-in-class Cancer Metabolism Program

    Apr 11, 2017 | 11:30 am

    Lead Discovery Center GmbH (http://www.lead-discovery.de/en/) (LDC), Max Planck Innovation GmbH (http://www.max-planck-innovation.de/en/) (MI) and SOTIO a.s. (http://www.sotio.com/) have signed a collaboration and license agreement providing SOTIO with exclusive rights to an oncology program addressing a novel target in tumor metabolism. It was discovered at the Max Planck

    Read more...
  • LifeCodexx and Charité to Form Research Alliance Following Successful Clinical Proof-Of Principle for Molecular Genetic-Based Preeclampsia Assay

    Apr 11, 2017 | 09:15 am

    LifeCodexx AG (http://lifecodexx.com/en/), a leading European NIPT provider, and the Department of Obstetrics of the Charité (https://www.charite.de/en/) have formed a research alliance to intensify research and development of a novel molecular genetic-based assay for the early detection of preeclampsia, a severe disorder in pregnancy characterized by hypertension and proteinuria after the 20th week of gestation. It is the cause of[…]

    Read more...
  • Asceneuron Receives Regulatory Approval for Phase I Healthy Volunteer Study of Oral Tau Inhibitor

    Apr 6, 2017 | 08:00 am

    Asceneuron SA (http://www.asceneuron.com/), an emerging leader in the development of innovative small molecules for neurodegenerative diseases, announced today the regulatory approval of its clinical trial application to initiate a first clinical study of ASN120290 (formerly known as ASN-561), belonging to a chemically novel group of O-GlcNAcase enzyme inhibitors. Based on preclinical studies, ASN120290 has the potential to become a

    Read more...
  • RedHill Biopharma Announces Exclusive U.S. License from Entera Health for Commercial GI Product EnteraGam®

    Apr 5, 2017 | 12:00 pm

    RedHill Biopharma Ltd. (http://www.redhillbio.com/) (NASDAQ: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal (GI)

    Read more...
  • RedHill Biopharma Receives FDA Orphan Drug Designation for YELIVA® for the Treatment of Cholangiocarcinoma

    Apr 4, 2017 | 10:30 am

    Orphan Drug designation allows RedHill to benefit from various development incentives to develop YELIVA® (ABC294640) for cholangiocarcinoma, as well as a seven-year marketing exclusivity period for the indication, if approved for marketingA Phase IIa clinical study with YELIVA® in patients with advanced, unresectable, intrahepatic and extrahepatic cholangiocarcinoma is planned to be initiated in the third quarter of 2017Cholangiocarcinoma (bile duct[…]

    Read more...
  • NBE-Therapeutics Expands Board of Directors by the Appointment of Hans-Peter Gerber

    Apr 4, 2017 | 10:00 am

    NBE Therapeutics AG (http://www.nbe-therapeutics.com), a biopharmaceutical company developing next generation ADC products based on its Transpo-mAb™ antibody platform, site-specific SMAC™ conjugation technology and novel ultra-potent toxin platform today announced the appointment of Hans-Peter Gerber to its Board of Directors.Hans-Peter has more than 20 years of research and development experience in the field of antibody-drug conjugates (ADC). Most recently he was[…]

    Read more...
  • Australia’s Bionic Vision Technologies Raises USD18 Million(AUD23.5 M) to Develop ‘Bionic Eye’ for Global Markets

    Apr 3, 2017 | 14:00 pm

    Bionic Vision Technologies (http://bionicvis.com/) (BVT) today announced it had raised US $18 million (AU$23.5 million) from Hong Kong-based China Huarong International Holdings Ltd and State Path Capital Limited, to develop and commercialise its next generation devices aimed at restoring vision to the blind.This financing formally launches the Company as it transitions to a commercialisation stage business. To date, the development[…]

    Read more...
  • Imanova Receives £1M Award from the MRC To Develop Early Markers of Dementia – the MIND-MAPS Study

    Apr 3, 2017 | 08:00 am

    Medical Research Council (http://www.mrc.ac.uk) (MRC) grant to implement new Positron Emission Tomography (PET) imaging tracers for mitochondrial dysfunction and synaptic loss, Imanova (http://www.imanova.co.uk/) has been awarded an additional £1m of strategic funding from the MRC for clinical evaluation of this combination of tracers in Alzheimer’s disease and Parkinson’s disease Stage 1 of the MIND-MAPS (Molecular Imaging of Neurodegenerative Disease –[…]

    Read more...
  • Calypso Biotech Licenses CALY-001 Best-In-Class Anti-MMP-9 Antibody to EA Pharma

    Mar 31, 2017 | 06:00 am

    B3C newswire (http://www.b3cnewswire.com/home.html) Calypso Biotech SA (http://www.calypsobiotech.com/site/en/) announced today that it has entered a global licensing and collaboration agreement with EA Pharma Co., Ltd (http://www.eapharma.co.jp/). to develop CALY-001, a best-in-class anti-MMP-9 fully human monoclonal antibody.CALY-001 is a promising novel treatment for indications such as inflammatory bowel disease (IBD), potentially capable of preventing disease complications.“This agreement highlights the strong potential for[…]

    Read more...